Perspectives on the Global Active Pharmaceutical Ingredient


Dublin, November 11, 2021 (GLOBE NEWSWIRE) – The “Active Pharmaceutical Ingredients Market Research Report: By Type of Manufacturer, Type, Type of Synthesis, Type of Drug, Therapeutic Application, Distribution Channel – Estimated Revenue of global industry until 2030 ‘report was added to offer.

The global active pharmaceutical ingredients market was valued at $ 184,311.2 million in 2020, and is expected to reach $ 357,005.7 million by 2030, demonstrating a CAGR of 6.9% of 2021 to 2030.

Mushrooming Geriatric Population: According to the World Health Organization (WHO), the increase in average life expectancy in recent years has caused a sharp increase in the elderly population. According to the World Population Aging 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 and over will grow from 727 million in 2020 to over 1.5 billion by 2050 As geriatric people are vulnerable to chronic and acute illnesses due to weak immune systems, their growing population is driving the need for effective drugs, hence fueling the expansion of API market.

Increasing Incidence of Chronic Diseases: People with sedentary lifestyles and the prevalence of obesity increasing, the incidence of various chronic diseases, such as diabetes, is skyrocketing around the world. According to the WHO, 422 million people are currently living with the disease and the disease kills 1.6 million each year. Being a long term illness, patients need constant medication, especially insulin.

The COVID-19 pandemic has amplified global demand for pharmaceuticals. Due to the growing number of patients, drug research and development activities, especially those aimed at finding an effective vaccine, have increased. In addition, the API market has been positively impacted by the growing demand for these products during the pandemic. For example, the Pharmaceutical Export Promotion Council (PHARMEXCIL) of India recorded a significant increase in the cost of penicillin, one of the best known antibiotics, from $ 6.16 per unit in January 2020 to 8.69 $ the unit in just one month.

In the past, the prescription drug category has contributed to the rise in API market revenue, under the drug segment type. The need for prescription drugs for the management of complex chronic diseases is increasing around the world, thus propelling the consumption of associated active ingredients.

The oncology category has dominated the API market in recent years, in the therapeutic applications segment. The high incidence of cancer is driving a growing need for highly potent APIs (HPAPIs). According to the American Cancer Society, by the end of 2021, nearly 1.9 million new cancer cases and 608,570 related deaths will be reported in the United States. Likewise, according to the WHO, there were 2,003,789 cases of various types of cancer in Southeast Asia in 2018. In addition, the disease claimed the lives of 1,336,026 people in the same year.

Geographically, North America is expected to dominate the API market in the coming years due to the increasing prevalence and awareness of chronic and lifestyle-related diseases, increasing government attention on generic drugs, growing needs for specialty drugs and biologics, rapid technological advancements, and an increasing number of pharmaceutical R&D activities in the region. For example, according to the Centers for Disease Control and Prevention (CDC), in 2018, chronic diseases cost the U.S. health care system $ 3.5 trillion.

The major players operating in the global API market are Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Novartis AG, Teva Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Alkem Laboratories Limited, MSN Laboratories Pvt. Ltd., AstraZeneca plc, GlaxoSmithKline plc, Mallinckrodt plc, Sun Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Lupine Limited, Mylan NV, Amneal Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson, Merck & Co. Inc., Glenmark Life Sciences Limited, Eli Lilly and Company and Sanofi.

Main topics covered:

Chapter 1. Research Context

Chapter 2. Research methodology

Chapter 3. Executive summary

Chapter 4. Voices of Industry Experts / KOL

Chapter 5. Market indicators
5.1 Aging of the world’s population
5.2 Global pharmaceutical market
5.2.1 Global Pharmaceutical Market Size
5.2.2 Breakdown of the global pharmaceutical market, by geography
5.2.3 The 10 best-selling drugs in the world
5.2.4 Major Players Global Pharmaceutical Market Share Analysis (2019)

Chapter 6. Definition of market segments
6.1 By type of manufacturer
6.1.1 Captive
6.1.2 Merchant
6.2 By type
6.2.1 Generic APIs
6.2.2 Innovative APIs
6.3 By type of synthesis
6.3.1 Biotechnology
6.3.2 Synthetic
6.4 By type of drug
6.4.1 Prescription drugs
6.4.2 Over-the-counter medications
6.5 By therapeutic application
6.5.1 Oncology
6.5.2 Antidiabetics
6.5.3 Anti-rheumatic drugs
6.5.4 Vaccines
6.5.5 Antiviral
6.5.6 Bronchodilators
6.5.7 Sensory organs
6.5.8 Anticoagulants
6.5.9 Immunosuppressants
6.5.10 Dermatological products
6.5.11 Others
6.6 By distribution channel
6.6.1 Offline
6.6.2 Online

Chapter 7. Industry Outlook
7.1 Market dynamics
7.1.1 Trends Partnerships and mergers and acquisitions Technological advancement in API manufacturing
7.1.2 Drivers Growing Geriatric Population Growing Incidence of Chronic Diseases Growing importance of generics Impact analysis of engines on market forecasts
7.1.3 Constraints High manufacturing costs Unfavorable drug price control policies Strict regulations Analysis of the impact of constraints on market forecasts
7.2 Impact of COVID-19 on the API market
7.3 Porter’s five forces analysis
7.3.1 Bargaining power of buyers
7.3.2 Bargaining power of suppliers
7.3.3 Intensity of rivalry
7.3.4 Threat of new entrants
7.3.5 Threat of substitutes

Chapter 8. Policy and regulatory landscape
8.1 North America
8.2 Europe
8.3 APAC
8.5 MEA

Chapter 9. Global Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Type of Manufacturer (2015-2030)
9.3 Market Revenue, by Type (2015-2030)
9.4 Market Revenue, by Synthesis Type (2015-2030)
9.5 Market Revenue, by Drug Type (2015-2030)
9.6 Market Revenue, by Therapeutic Application (2015-2030)
9.7 Market Revenue, by Distribution Channel (2015-2030)
9.8 Market Revenue, by Region (2015-2030)

Chapter 10. North America Market Size and Forecast

Chapter 11. Europe Market Size and Forecast

Chapter 12. APAC Market Size and Forecast

Chapter 13. LATAM Market Size and Forecast

Chapter 14. MEA Market Size and Forecast

Chapter 15. US Market Size and Forecast

Chapter 16. Canadian Market Size and Forecast

Chapter 17. German Market Size and Forecast

Chapter 18. France Market Size and Forecast

Chapter 19. UK Market Size and Forecast

Chapter 20. Italian Market Size and Forecast

Chapter 21. Spanish Market Size and Forecast

Chapter 22. Japan Market Size and Forecast

Chapter 23. China Market Size and Forecast

Chapter 24. India Market Size and Forecast

Chapter 25. Australia Market Size and Forecast

Chapter 26. South Korea Market Size and Forecast

Chapter 27. Brazil Market Size and Forecast

Chapter 28. Mexico Market Size and Forecast

Chapter 29. Saudi Arabia Market Size and Forecast

Chapter 30. UAE Market Size and Forecast

Chapter 31. Competitive landscape
31.1 Main API molecules
31.2 Revenue Comparison of Major Players
31.3 Global strategic developments
31.3.1 Partnerships
31.3.2 Product Launches and Expansion
31.3.3 Mergers & Acquisitions

Chapter 32. Company Profiles
32.1 Cipla SA
32.1.1 Company overview
32.1.2 Product and service offerings
32.1.3 Key financial summary
32.2 Dr Reddy’s Laboratories Ltd.
32.2.1 Company overview
32.2.2 Product and service offerings
32.2.3 Key financial summary
32.3 Teva Pharmaceutical Industries Limited
32.3.1 Company Overview
32.3.2 Product and service offerings
32.3.3 Key financial summary
32.4 Aurobindo Pharma Limited
32.4.1 Company Overview
32.4.2 Product and service offerings
32.4.3 Key financial summary
32.5 Novartis AG
32.5.1 Company overview
32.5.2 Product and service offerings
32.5.3 Key financial summary
32.6 Pfizer Inc.
32.6.1 Company overview
32.6.2 Product and service offerings
32.6.3 Key Financial Summary
32.7 Bristol-Myers Squibb Company
32.7.1 Company overview
32.7.2 Product and service offerings
32.7.3 Key financial summary
32.8 Glenmark Life Sciences Limited
32.8.1 Company overview
32.8.2 Product and service offerings
32.8.3 Key financial summary
32.9 Johnson & Johnson
32.9.1 Company overview
32.9.2 Product and service offerings
32.9.3 Key Financial Summary
32.10 Merck & Co. Inc.
32.10.1 Company overview
32.10.2 Product and service offerings
32.10.3 Key Financial Summary
32.11 AbbVie Inc.
32.11.1 Company Overview
32.11.2 Product and service offerings
32.11.3 Key financial summary
32.12 Eli Lilly and company
32.12.1 Company overview
32.12.2 Product and service offerings
32.12.3 Key financial summary
32.13 GlaxoSmithKline plc
32.13.1 Company Overview
32.13.2 Product and service offerings
32.13.3 Key financial summary
32.14 Sanofi
32.14.1 Company Overview
32.14.2 Product and service offerings
32.14.3 Key financial summary
32.15 Takeda Pharmaceutical Company Limited
32.15.1 Company Overview
32.15.2 Product and service offerings
32.15.3 Key financial summary
32.16 Amneal Pharmaceuticals Inc.
32.16.1 Company Overview
32.16.2 Product and service offerings
32.16.3 Key financial summary
32.17 AstraZeneca plc
32.17.1 Company Overview
32.17.2 Product and service offerings
32.17.3 Key financial summary
32.18 Sun Pharmaceutical Industries Ltd.
32.18.1 Company Overview
32.18.2 Product and service offerings
32.18.3 Key financial summary
32.19 Alkem Laboratories Limited
32.19.1 Company Overview
32.19.2 Product and service offerings
32.19.3 Key financial summary
32.20 Mylan SA
32.20.1 Company overview
32.20.2 Product and service offerings
32.20.3 Key financial summary
32.21 Lupine Limited
32.21.1 Company Overview
32.21.2 Product and service offerings
32.21.3 Key financial summary
32.22 STADA Arzneimittel AG
32.22.1 Company Overview
32.22.2 Product and service offerings
32.22.3 Key financial summary
32.23 Mallinckrodt plc
32.23.1 Company Overview
32.23.2 Product and service offerings
32.23.3 Key financial summary
32.24 Glenmark Life Sciences Limited
32.24.1 Company Overview
32.24.2 Product and service offerings
32.24.3 Key financial summary
32.25 MSN Laboratories Pvt. Ltd.
32.25.1 Company Overview
32.25.2 Product and service offerings

Chapter 33. Appendix

For more information on this report, visit


Leave A Reply